The Role of Secondary Surgery in Recurrent Ovarian Cancer

Lorusso, Domenica; Mancini, Maria; Rocco, Roberta Di; Fontanelli, Rosanna; Raspagliesi, Francesco

doi:10.1155/2012/613980

Cited by 25 publications

(20 citation statements)

References 40 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…70 One clear factor in the consideration for surgical intervention in medically fit patients is their underlying potential to respond to adjuvant therapy. Although this is an imperfect science, the probability of responding to secondary chemotherapy seems to be a positively sloped linear relationship with treatment and platinum-free interval.…”

Section: Recurrent Disease Therapymentioning

confidence: 99%

Latest research and treatment of advanced-stage epithelial ovarian cancer

et al. 2013

View full text Add to dashboard Cite

The natural history of ovarian cancer continues to be characterized by late-stage presentation, metastatic bulky disease burden and stagnant mortality statistics despite prolific drug development. Robust clinical investigation, particularly with modifications to primary treatment surgical goals and adjuvant therapy are increasing median progression-free and overall survival, although the cure rates have only modestly been affected. Maintenance therapy holds promise, but studies have yet to identify an agent and/or strategy that can affect survival. Recurrent disease is largely an incurable state; however, current intervention with selected surgery, combination and targeted therapy and investigational protocols are impacting progression-free survival. Ovarian cancer is a diverse and genomically complex disease, which commands global attention. Rational investigation must balance the high rate of discovery with lagging clinical investigation and limited patient resources. Nevertheless, armamentarium growth offers unprecedented opportunities for patients suffering with this disease. This Review presents and reviews the contemporary management of the disease spectrum termed epithelial ‘ovarian’ cancer and introduces the direction and early results of clinical investigation.

show abstract

Section: Recurrent Disease Therapymentioning

confidence: 99%

Latest research and treatment of advanced-stage epithelial ovarian cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The role of SCS in recurrent ovarian cancer treatment has not been clearly defined, and conclusive evidence is lacking (6,(27)(28)(29). The role of SCS in recurrent ovarian cancer treatment has not been clearly defined, and conclusive evidence is lacking (6,(27)(28)(29).…”

Section: Discussionmentioning

confidence: 99%

Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum‐sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry‐based study

Szczesny

Langseth

Myklebust

et al. 2018

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

In selected epithelial ovarian cancer patients with no residuals after primary surgery and a recurrent, platinum-sensitive tumor, the complete resection of recurrent tumor at secondary cytoreductive surgery improves progression-free survival and overall survival. Our results suggest that a long treatment-free interval and non-disseminated lesions (three or fewer lesions) on radiological images could be useful predictors for complete resection at secondary cytoreductive surgery.

show abstract

“…Because the ovaries are located deep in the pelvic cavity and are not easily palpated, and early‐stage ovarian cancer often has no obvious symptoms, 70% of patients with ovarian cancer have advanced‐stage disease at the time of diagnosis . In addition, although therapies such as surgery and chemotherapy continue to improve, the 5‐year survival rate of patients with advanced ovarian cancer remains approximately 30%, and the prognosis is poor …”

Section: Introductionmentioning

confidence: 99%

Diagnostic value of derived neutrophil‐to‐lymphocyte ratio in patients with ovarian cancer

Qin

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundInflammation plays an important role in the occurrence and development of cancer. Numerous studies have used the derived neutrophil‐to‐lymphocyte ratio (dNLR) to evaluate prognosis in many types of cancer. However, the relationship between dNLR and ovarian cancer and its value in the differential diagnosis of benign and malignant ovarian tumors remain unknown.MethodsA total of 262 patients with ovarian cancer, 258 with benign ovarian disease, and 232 healthy controls were included in this study. dNLR was calculated using whole blood cell parameters. Receiver operating characteristic curves were generated to obtain sensitivity, specificity, and area under the ROC curve (AUC) to evaluate the diagnostic values of dNLR.ResultsdNLR was significantly different among the ovarian cancer, benign ovarian disease, and healthy control groups (all P < 0.001). Moreover, there were significant differences in dNLR between patients with early‐stage (I and II) and advanced‐stage (III and IV) disease (P < 0.001). dNLR was positively correlated with stage and carbohydrate antigen‐125 in ovarian cancer. A cutoff value of dNLR ≤2.11 was diagnostic in distinguishing ovarian cancer from benign ovarian disease with AUC of 0.729 (95% confidence interval [CI], 0.689‐0.767; P = 0.0001). A cutoff value of dNLR ≤1.9 was diagnostic in distinguishing ovarian cancer from healthy controls with an AUC of 0.821 (95% CI, 0.784‐0.854; P = 0.0001).ConclusiondNLR may be a useful indicator for distinguishing between ovarian cancer and benign ovarian disease and for identifying early and advanced ovarian cancer.

show abstract

The Role of Secondary Surgery in Recurrent Ovarian Cancer

Cited by 25 publications

References 40 publications

Latest research and treatment of advanced-stage epithelial ovarian cancer

Latest research and treatment of advanced-stage epithelial ovarian cancer

Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum‐sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry‐based study

Diagnostic value of derived neutrophil‐to‐lymphocyte ratio in patients with ovarian cancer

Contact Info

Product

Resources

About